FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2467202497> ?p ?o ?g. }

• W2467202497 endingPage "22" @default.
• W2467202497 startingPage "15" @default.
• W2467202497 abstract "Background Venous thromboembolic events (VTEs) are common and potentially fatal complications in cancer patients, and they are responsible for the second most common cause of death. Low molecular weight heparin (LMWH) is the gold-standard treatment, but the costs involved limit its use, especially in developing countries. Recently, the oral anticoagulant rivaroxaban, which directly inhibits factor Xa, was approved for VTE treatment. Methods We conducted a retrospective analysis from January 2009 to February 2014 with patients who had cancer and VTE who were receiving rivaroxaban. We compared the efficacy, safety, and cost of rivaroxaban and low molecular weight heparin (LMWH) alone or followed by vitamin K antagonists. Results Forty-one patients were identified, with a median age of 62.5 years. The most frequent tumor histology was adenocarcinoma (78%), which was most often found in the colon (26.8%). Most participants had advanced disease and an implanted central venous catheter. Patients’ VTE risk-assessment scores were low (12.5%), intermediate (50%), and high (35.5%). Pulmonary thromboembolism was reported in 41.4% of patients, but inferior limb thrombosis was reported only in 14.6%; 43.9% of patients received enoxaparin before starting rivaroxaban. Rivaroxaban was used for a median time of 5.5 months. Nonmajor bleeding was reported in 12.2% of patients, and rethrombosis was reported in 12.2%. In our study, rivaroxaban was as safe and effective as enoxaparin/vitamin K antagonists ( P = .54 and P = .25, respectively) or LMWH ( P = .46 and P = .29, respectively). Conclusion Although our study was a retrospective analysis, our results suggest that in this cohort of oncologic patients, rivaroxaban was safe and effective. Its oral route and lower cost make it an attractive alternative to LMWH, improving management of patients with cancer in low-income countries. Additional studies are necessary to confirm our data." @default.
• W2467202497 created "2016-07-22" @default.
• W2467202497 creator A5009974709 @default.
• W2467202497 creator A5013692267 @default.
• W2467202497 creator A5036877489 @default.
• W2467202497 creator A5063691329 @default.
• W2467202497 creator A5066337859 @default.
• W2467202497 creator A5072207853 @default.
• W2467202497 creator A5075080955 @default.
• W2467202497 creator A5080628857 @default.
• W2467202497 creator A5083247015 @default.
• W2467202497 date "2017-02-01" @default.
• W2467202497 modified "2023-10-16" @default.
• W2467202497 title "Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?" @default.
• W2467202497 cites W1675801983 @default.
• W2467202497 cites W1948889300 @default.
• W2467202497 cites W1966556597 @default.
• W2467202497 cites W1970642927 @default.
• W2467202497 cites W1978080273 @default.
• W2467202497 cites W1996600303 @default.
• W2467202497 cites W1998106433 @default.
• W2467202497 cites W2013984355 @default.
• W2467202497 cites W2049526508 @default.
• W2467202497 cites W2054324054 @default.
• W2467202497 cites W2078558642 @default.
• W2467202497 cites W2089463803 @default.
• W2467202497 cites W2096134439 @default.
• W2467202497 cites W2102967512 @default.
• W2467202497 cites W2115019673 @default.
• W2467202497 cites W2117662968 @default.
• W2467202497 cites W2130199362 @default.
• W2467202497 cites W2132300233 @default.
• W2467202497 cites W2161174900 @default.
• W2467202497 cites W2166383168 @default.
• W2467202497 cites W2167494200 @default.
• W2467202497 cites W2169375165 @default.
• W2467202497 cites W2313284959 @default.
• W2467202497 cites W2469615673 @default.
• W2467202497 cites W4232932258 @default.
• W2467202497 cites W4238209717 @default.
• W2467202497 cites W4247355438 @default.
• W2467202497 cites W4323283745 @default.
• W2467202497 doi "https://doi.org/10.1200/jgo.2015.002527" @default.
• W2467202497 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5493228" @default.
• W2467202497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28717737" @default.
• W2467202497 hasPublicationYear "2017" @default.
• W2467202497 type Work @default.
• W2467202497 sameAs 2467202497 @default.
• W2467202497 citedByCount "10" @default.
• W2467202497 countsByYear W24672024972017 @default.
• W2467202497 countsByYear W24672024972018 @default.
• W2467202497 countsByYear W24672024972019 @default.
• W2467202497 crossrefType "journal-article" @default.
• W2467202497 hasAuthorship W2467202497A5009974709 @default.
• W2467202497 hasAuthorship W2467202497A5013692267 @default.
• W2467202497 hasAuthorship W2467202497A5036877489 @default.
• W2467202497 hasAuthorship W2467202497A5063691329 @default.
• W2467202497 hasAuthorship W2467202497A5066337859 @default.
• W2467202497 hasAuthorship W2467202497A5072207853 @default.
• W2467202497 hasAuthorship W2467202497A5075080955 @default.
• W2467202497 hasAuthorship W2467202497A5080628857 @default.
• W2467202497 hasAuthorship W2467202497A5083247015 @default.
• W2467202497 hasBestOaLocation W24672024971 @default.
• W2467202497 hasConcept C121608353 @default.
• W2467202497 hasConcept C126322002 @default.
• W2467202497 hasConcept C141071460 @default.
• W2467202497 hasConcept C167135981 @default.
• W2467202497 hasConcept C2776265017 @default.
• W2467202497 hasConcept C2776301958 @default.
• W2467202497 hasConcept C2776704044 @default.
• W2467202497 hasConcept C2776884760 @default.
• W2467202497 hasConcept C2778205648 @default.
• W2467202497 hasConcept C2778661090 @default.
• W2467202497 hasConcept C2779161974 @default.
• W2467202497 hasConcept C2780011451 @default.
• W2467202497 hasConcept C2780868729 @default.
• W2467202497 hasConcept C71924100 @default.
• W2467202497 hasConceptScore W2467202497C121608353 @default.
• W2467202497 hasConceptScore W2467202497C126322002 @default.
• W2467202497 hasConceptScore W2467202497C141071460 @default.
• W2467202497 hasConceptScore W2467202497C167135981 @default.
• W2467202497 hasConceptScore W2467202497C2776265017 @default.
• W2467202497 hasConceptScore W2467202497C2776301958 @default.
• W2467202497 hasConceptScore W2467202497C2776704044 @default.
• W2467202497 hasConceptScore W2467202497C2776884760 @default.
• W2467202497 hasConceptScore W2467202497C2778205648 @default.
• W2467202497 hasConceptScore W2467202497C2778661090 @default.
• W2467202497 hasConceptScore W2467202497C2779161974 @default.
• W2467202497 hasConceptScore W2467202497C2780011451 @default.
• W2467202497 hasConceptScore W2467202497C2780868729 @default.
• W2467202497 hasConceptScore W2467202497C71924100 @default.
• W2467202497 hasIssue "1" @default.
• W2467202497 hasLocation W24672024971 @default.
• W2467202497 hasLocation W24672024972 @default.
• W2467202497 hasLocation W24672024973 @default.
• W2467202497 hasLocation W24672024974 @default.
• W2467202497 hasOpenAccess W2467202497 @default.
• W2467202497 hasPrimaryLocation W24672024971 @default.

• next